The role of heparan sulfate and perlecan in bone-regenerative procedures

Journal of Dental Research

Volumn 85, Issue 2, 2006, Pages 122-132

  DeCarlo, A A ^a   Whitelock, J M ^b  

^a Agenta Biotechnologies Inc   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Angiogenesis; Healing; Heparan sulfate; Perlecan; Regeneration

Indexed keywords

GROWTH PROMOTOR; PERLECAN; PROTEOHEPARAN SULFATE;

ANIMAL; BONE PROSTHESIS; BONE REGENERATION; CELL ADHESION; CHEMISTRY; DRUG EFFECT; HUMAN; OSTEOLYSIS; PERIODONTICS; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; REVIEW;

ALVEOLAR BONE LOSS; ANIMALS; BONE REGENERATION; BONE SUBSTITUTES; CELL ADHESION; GROWTH SUBSTANCES; GUIDED TISSUE REGENERATION, PERIODONTAL; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; PROTEIN STRUCTURE, TERTIARY;

EID: 33744805071     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910608500203     Document Type: Review

References (107)

1. Amar S, Petrungaro P, Amar A, Van Dyke TE (1995). Immunolocalization of bone matrix macromolecules in human tissues regenerated from periodontal defects treated with expanded polytetrafluoroethylene membranes. Arch Oral Biol 40:653-661.
2. Andriessen MP, van den Born J, Latijnhouwers MA, Bergers M, van de Kerkhof PC, Schalkwijk J (1997). Basal membrane heparan sulphate proteoglycan expression during wound healing in human skin. J Pathol 183:264-271.
3. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A (1994). Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79:1005-1013.
4. Aviezer D, Iozzo RV, Noonan DM, Yayon A (1997). Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol 17:1938-1946.
5. Banesh-Meyer MJ (2000). Tissue engineering in periodontics using rhBMP-2. J New Zeal Soc Periodent 85:10-14.
6. Basak SK, Kiertscher SM, Harui A, Roth MD (2004). Modifying adenoviral vectors for use as gene-based cancer vaccines. Viral Immunol 17:182-196.
7. Battaglia C, Aumailley M, Mann K, Mayer U, Timpl R (1993). Structural basis of beta-1 integrin-mediated cell adhesion to a large heparan sulfate proteoglycan from basement membranes. Eur J Cell Biol 61:92-99.
8. Beck JD, Offenbacher S, Williams R, Gibbs P, Garcia R (1998). Periodontitis: a risk factor for coronary heart disease? Ann Periodontol 3:127-141.
9. Boden SD (2002). Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine 27:S26-S31.
10. Brown JC, Sasaki T, Gohring W, Yamada Y, Timpl R (1997). The C-terminal domain V of perlecan promotes betal integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem 250:39-46.
11. Bucholz RW (2002). Nonallograft osteoconductive bone graft substitutes. Clin Orthop Rel Res 395:44-52.
12. Carranza FA, Newman MG, Takei HH (2002). Carranza's clinical periodontology. 9th ed. Philadelphia: W.B. Saunders Co.
13. Carson DD, Tang JP, Julian J (1993). Heparan sulfate proteoglycan (perlecan) expression by mouse embryos during acquisition of attachment competence. Dev Biol 155:97-106.
14. Chakravarti S, Horchar T, Jefferson B, Laurie GW, Hassell JR (1995). Recombinant domain III of perlecan promotes cell attachment through its RODS sequence. J Biol Chem 270:404-409.
15. Chan I (2004). The role of extracellular matrix protein 1 in human skin. Clin Exp Dermatol 29:52-56.
16. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR (1996). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 94:1645-1650.
17. Cortellini P, Bowers GM (1995). Periodontal regeneration of intrabony defects: an evidence-based treatment approach. Int J Periodont Rest Dent 15:128-145.
18. Cortellini P, Tonetti MS, Lang NP, Suvan JE, Zucchelli G, Vangsted T, et al. (2001). The simplified papilla preservation flap in the regenerative treatment of deep intrabony defects: clinical outcomes and postoperative morbidity. J Periodontol 72:1702-1712.
19. Crombleholme TM (2000). Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen 8:460-472.
20. Croyle MA, Anderson DJ, Roessler BJ, Amidon GL (1998). Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery. Pharm Dev Technol 3:365-372.
21. De Ranieri A, Virdi AS, Kuroda S, Shott S, Leven RM, Hallab NJ, et al. (2005). Local application of rhTGF-beta2 enhances peri-implant bone volume and bone-implant contact in a rat model. Bone 37:55-62.
22. Dias RA, Shibata S, Hashimoto-Uoshima M, Podyma-Inoue KA, Ishikawa I, Yanagishita M (2005). Syndecan-1 expression during the formation of junctional epithelium. J Periodontol 76:696-704.
23. Dodge GR, Boesler EW, Jimenez SA (1995). Expression of the basement membrane heparan sulfate proteoglycan (perlecan) in human synovium and in cultured human synovial cells. Lab Invest 73:649-657.
24. Donos N, Kostopoulos L, Karring T (2002). Alveolar ridge augmentation using a resorbable copolymer membrane and autogenous bone grafts. An experimental study in the rat. Clin Oral Implants Res 13:203-213.
25. Dorfer CE, Kim TS, Steinbrenner H, Holle R, Eickholz P (2000). Regenerative periodontal surgery in interproximal intrabony defects with biodegradable barriers. J Clin Periodontol 27:162-168.
26. Evans GH, Yukna RA, Cambre KM, Gardiner DL (1997). Clinical regeneration with guided tissue barriers. Curr Opin Periodonol 4:75-81.
27. Falk H, Laurell L, Ravald N, Teiwik A, Persson R (1997). Guided tissue regeneration therapy of 203 consecutively treated intrabony defects using a bioabsorbable matrix barrier. Clinical and radiographic findings. J Periodontol 68:571-581.
28. Finkemeier CG (2002). Bone-grafting and bone-graft substitutes. J Bone Joint Surg Am 84(A):454-464.
29. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, et al. (2001). Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83(A Suppl)1:S151-S158.
30. Fuki IV, Iozzo RV, Williams KJ (2000). Perlecan heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism. J Biol Chem 275:25742-25750.
31. Gauer S, Schulze-Lohoff E, Schleicher E, Sterzel RB (1996). Glomerular basement membrane-derived perlecan inhibits mesangial cell adhesion to fibronectin. Eur J Cell Biol 70:233-242.
32. Geesink RG, Hoefnagels NH, Bulstra SK (1999). Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 81:710-718.
33. Ghiselli G, Eichstetter I, Iozzo RV (2001). A role for the perlecan protein core in the activation of the keratinocyte growth factor receptor. Biochem J 359:153-163.
34. Giannobile WV, Hernandez RA, Finkelman RD, Ryan S, Kiritsy CP, D'Andrea M, et al. (1996). Comparative effects of platelet-derived growth factor-BB and insulin-like growth factor-I, individually and in combination, on periodontal regeneration in Macaca fascicularis. J Periodontal Res 31:301-312.
35. Giannobile WV, Ryan S, Shih MS, Su DL, Kaplan PL, Chan TC (1998). Recombinant human osteogenic protein-1 (OP-1) stimulates periodontal wound healing in class III furcation defects. J Periodontol 69:129-137.
36. Gomez-Foix AM, Coats WS, Baque S, Alam T, Gerard RD, Newgard CB (1992). Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem 267:25129-25134.
37. Graham LD, Whitelock JM, Underwood PA (1999). Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Biochem Biophys Res Commun 256:542-548.
38. Groffen AJ, Buskens CA, Tryggvason K, Veerkamp JH, Monnens LA, van den Heuvel LP (1996). Expression and characterization of human perlecan domains I and II synthesized by baculovirus-infected insect cells. Eur J Biochem 241:827-834.
39. Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, et al. (1997). Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol 68:713-719.
40. Gurinsky BS, Mills MP, Mellonig JT (2004). Clinical evaluation of demineralized freeze-dried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans. J Periodontol 75:1309-1318.
41. Hagen SG, Michael AF, Butkowski RJ (1993). Immunochemical and biochemical evidence for distinct basement membrane heparan sulfate proteoglycans. J Biol Chem 268:7261-7269.
42. Hanna R, Trejo PM, Weltman RL (2004). Treatment of intrabony defects with bovine-derived xenograft alone and in combination with platelet-rich plasma: a randomized clinical trial. J Periodontol 75:1668-1677.
43. Hassell JR, Robey PG, Barrach H-J, Wilczek J, Rennard SI, Martin GR (1980). Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc Natl Acad Sci USA 77:4494-4498.
44. Hayashi K, Madri JA, Yurchenco PD (1992). Endothelial cells interact with the core protein of basement membrane perlecan through beta1 and beta3 integrins-an adhesion modulated by glycosaminoglycan. J Cell Biol 119:945-959.
45. Heitz-Mayfield LJ, Schatzle M, Löe H, Burgin W, Anerud A, Boysen H, et al. (2003). Clinical course of chronic periodontitis. II. Incidence, characteristics and time of occurrence of the initial periodontal lesion. J Clin Periodontol 30:902-908.
46. Hoffman A, Weich HA, Gross G, Hillman G (2001). Perspectives in the biological function, the technical and therapeutic application of bone morphogenetic proteins. Appl Micro Biotech 57:294-308.
47. Hopf M, Gohring W, Kohfeldt E, Yamada Y, Timpl R (1999). Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. Eur J Biochem 259:917-925.
48. Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE (1997). A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. J Periodontol 68:1186-1193.
49. Ikarashi T, Ida-Yonemochi H, Ohshiro K, Cheng J, Saku T (2004). Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan, reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 33:87-95.
50. Iozzo RV, Danielson KG (1999). Transcriptional and posttranscriptional regulation of proteoglycan gene expression. Prog Nucleic Acid Res Mol Biol 62:19-53.
51. Ivanovski S, Li H, Daley T, Bartold PM (2000). An immunohistochemical study of matrix molecules associated with barrier membrane-mediated periodontal wound healing. J Periodontal Res 35:115-126.
52. Johnsson R, Stromqvist B, Aspenberg P (2002). Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine 27:2654-2661.
53. King GN (2001). The importance of drug delivery to optimize the effects of bone morphogenetic proteins during periodontal regeneration. Curr Pharmacol Biotechnol 2:131-142.
54. Klein G, Conzelmann S, Beck S, Timpl R, Muller CA (1995). Perlecan in human bone marrow: a growth-factor-presenting, but anti-adhesive, extracellular matrix component for hematopoietic cells. Matrix Biol 14:457-465.
55. Kogler G, Sensken S, Airey JA, Trapp T, Muschen M, Feldhahn N, et al. (2004). A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 200:123-135.
56. Lafont J, Blanquaert F, Colombier ML, Barritault D, Carueelle JP, Saffar JL (2004). Kinetic study of early regenerative effects of RGTA11, a heparan sulfate mimetic, in rat craniotomy defects. Calcif Tissue Int 75:517-525.
57. Larjava H, Hakkinen L, Rahemtulla F (1992). A biochemical analysis of human periodontal tissue proteoglycans. Biochem J 284:267-274.
58. Laurell L, Gottlow J, Zybutz M, Persson R (1998). Treatment of intrabony defects by different surgical procedures. A literature review. J Periodontol 69:303-313.
59. Lind M (1998). Growth factor stimulation of bone healing. Effects on osteoblasts, osteomies, and implants fixation. Acta Orthop Scand Suppl 283:2-37.
60. Löe H, Anerud A, Boysen H, Morrison E (1986). Natural history of periodontal disease in man. Rapid, moderate and no loss of attachment in Sri Lankan laborers 14-46 years of age. J Clin Periodontol 13:431-445.
61. Lynch SE, de Castilla GR, Williams RC, Kiritsy CP, Howell TH, Reddy MS, et al. (1991). The effects of short-term application of a combination of platelet-derived and insulin-like growth factors on periodontal wound healing. J Periodontol 62:458-467.
62. Machtei EE (2001). The effect of membrane exposure on the outcome of regenerative procedures in humans: a meta-analysis. J Periodontol 72:512-516.
63. Mack JA, Abramson SR, Ben Y, Coffin JC, Rothrock JK, Maytin EV, et al. (2003). Hoxb13 knockout adult skin exhibits high levels of hyaluronan and enhanced wound healing. FASEB J 17:1352-1354.
64. Marshall LJ, Ramdin LS, Brooks T, Charlton P, Shute JK (2003). Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 171:2057-2065.
65. Mehrara BJ, Saadeh PB, Steinbrech DS, Dudziak M, Specter JA, Greenwald JA, et al. (1999). Adenovirus-mediated gene therapy of osteoblasts in vitro and in vivo. J Bone Miner Res 14:1290-1301.
66. Meinel L, Zoidis E, Zapf J, Hassa P, Hottiger MO, Auer JA, et al. (2003). Localized insulin-like growth factor I delivery to enhance new bone formation. Bone 33:660-672.
67. Minabe M, Kodama T, Kogou T, Takeuchi K, Fushimi H, Sugiyama T, et al. (2002). A comparative study of combined treatment with a collagen membrane and enamel matrix proteins for the regeneration of intraosseous defects. Int J Periodont Rest Dent 22:595-605.
68. Mongiat M, Otto J, Oldershaw R, Ferrer F, Sato JD, Iozzo RV (2001). Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J Biol Chem 30:10263-10271.
69. Mongiat M, Fu J, Oldershaw R, Greenhalgh R, Gown AM, Iozzo RV (2003). Perlecan protein core interacts with extracellular matrix protein 1 (ECM 1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem 278:17491-17499.
70. Mummaneni PV, Pan J, Haid RW, Rodts GE (2004). Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 1:19-23.
71. Murdoch AD, Dodge GR, Cohen I, Tuan RS, Iozzo RV (1992). Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan)-a chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Biol Chem 267:8544-8557.
72. Murdoch AD, Liu B, Schwarting R, Tuan RS, Iozzo RV (1994). Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 42:239-249.
73. Needleman I, Tucker R, Giedrys-Leeper E, Worthington H (2005). Guided tissue regeneration for periodontal intrabony defects-a Cochrane Systematic Review. Periodontol 2000 37:106-123.
74. Needleman IG, Giedrys-Leeper E, Tucker RJ (2001). Guided tissue regeneration for periodontal infra-bony defects. Cochrane Database Systematic Reviews, issue 2, pp. CD001724, accession no. 11406001. http://www.ncbi.nlm.nih. gov/entrez/query.fogi?cmd=Retrieve&db=PubMed&dopt=Citation& list_uids=11406001
75. Nevins M, Camelo M, Nevins ML, Schenk RK, Lynch SE (2003). Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone. J Periodontol 74:1282-1292.
76. Newell DH (1998). The diagnosis and treatment of molar furcation invasions. Dent Clin North Am 42:301-337.
77. Noonan DM, Fulle A, Valente P, Cai S, Horigan E, Sasaki M, et al. (1991). The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J Biol Chem 266:22939-22947.
78. Nugent MA, Iozzo RV (2000). Fibroblast growth factor-2. Int J Biochem Cell Biol 32:115-120.
79. Offenbacher S, Jared HL, O'Reilly PG, Wells SR, Salvi GE, Lawrence HP, et al. (1998). Potential pathogenic mechanisms of periodontitis associated pregnancy complications. Ann Periodontol 3:233-250.
80. Parashis A, Andronikaki-Faldami A, Tsiklakis K (2004). Clinical and radiographic comparison of three regenerative procedures in the treatment of intrabony defects. Int J Periodont Rest Dent 24:81-90.
81. Pitaru S, Noff M, Grosskopf A, Moses O, Tal H, Savion N (1991). Heparan sulfate and fibronectin improve the capacity of collagen barriers to prevent apical migration of the junctional epithelium. J Periodontol 62:598-601.
82. Rops AL, van der Vlag J, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH, et al. (2004). Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 65:768-785.
83. Rose FR, Oreffo RO (2002). Bone tissue engineering: hope vs hype. Biochem Biophys Res Commun 292:1-7.
84. Saku T, Furthmayr H (1989). Characterisation of the major heparan sulfate proteoglycan secreted by bovine aortic endothelial cells in culture. J Biol Chem 264:3514-3523.
85. Sammarco VJ, Chang L (2002). Modem issues in bone graft substitutes and advances in bone tissue technology. Foot Ankle Clin 7:19-41.
86. Sanz M, Tonetti MS, Zabalegui I, Sicilia A, Blanco J, Rebelo H, et al. (2004). Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial. J Periodontol 75:726-733.
87. Schilephake H (2002). Bone growth factors in maxillofacial skeletal reconstruction. Int J Oral Maxillofac Surg 31:469-484.
88. Sculean A, Windisch P, Keglevich T, Gera I (2005). Clinical and histologic evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. Int J Periodont Rest Dent 25:139-147.
89. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, Iozzo RV (1998). Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 102:1599-1608.
90. Shi Z, Zeng M, Yang G, Siegel F, Cain LJ, van Kampen KR, et al. (2001). Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 75:11474-11482.
91. Silvestri M, Sartori S, Rasperini G, Ricci G, Rota C, Cattaneo V (2003). Comparison of infrabony defects treated with enamel matrix derivative versus guided tissue regeneration with a nonresorbable membrane. J Clin Periodontol 30:386-393.
92. Spillmann D, Witt D, Lindahl U (1998). Defining the interleukin-8-binding domain of heparan sulfate. J Biol Chem 273:15487-15493.
93. SundarRaj N, Fite D, Ledbetter S, Chakravarti S, Hassell JR (1995). Perlecan is a component of cartilage matrix and promotes chondrocyte attachment. J Cell Sci 108:2663-2672.
94. SundarRaj N, Fite D, Belak R, Sudarraj S, Rada J, Okamoto S, et al. (1998). Proteoglycan distribution during healing of corneal stromal wounds in chick. Exp Eye Res 67:433-442.
95. Tolsma SS, Stack MS, Bouck N (1997). Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1. Microvasc Res 54:13-26.
96. Vandana KL, Shah K, Prakash S (2004). Clinical and radiographic evaluation of Emdogain as a regenerative material in the treatment of interproximal vertical defects in chronic and aggressive periodontitis patients. Int J Periodont Rest Dent 24:185-191.
97. Vischer P, Feitsma K, Schon P, Volker W (1997). Perlecan is responsible for thrombospondin 1 binding on the cell surface of cultured porcine endothelial cells. Eur J Cell Biol 73:332-343.
98. Wang HL, Al-Shammari K (2002). HVC ridge deficiency classification: a therapeutically oriented classification. Int J Periodont Rest Dent 22:335-343.
99. Warrer K, Karring T (1992). Guided tissue regeneration combined with osseous grafting in suprabony periodontal lesions. An experimental study in the dog. J Clin Periodontol 19:373-380.
100. Whitelock JM, Iozzo RV (2002). Isolation and purification of proteoglycans. Meth Cell Biol 69:53-67.
101. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996). The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271:10079-10086.
102. Whitelock JM, Graham LD, Melrose J, Murdoch AD, Iozzo RV, Underwood PA (1999). Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol 18:163-178.
103. Wiltfang J, Schlegel KA, Schultze-Mosgau S, Nkenke E, Zimmermann R, Kessler P (2003). Sinus floor augmentation with beta-tricalcium-phosphate (beta-TCP): does platelet-rich plasma promote its osseous integration and degradation? Clin Oral Implants Res 14:213-218.
104. Yu WH, Woessner JF Jr (2000). Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J Biol Chem 275:4183-4191.
105. Zeichner-David M (2001). Is there more to enamel matrix proteins than biomineralization? Matrix Biol 20:307-316.
106. Zhou Z, Wang J, Cao R, Morita H, Soininen R, Chan KM, et al. (2004). Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res 64:4699-4702.
107. Zucchelli G, Amore C, Montebugnoli L, De Sanctis M (2003). Enamel matrix proteins and bovine porous bone mineral in the treatment of intrabony defects: a comparative controlled clinical trial. J Periodontol 74:1725-1735